Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $43.14

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been assigned an average rating of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $43.1429.

A number of equities analysts have commented on the stock. Royal Bank Of Canada cut their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. B. Riley raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. TD Cowen raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 28th. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $38.19 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $39.42. The stock has a market cap of $5.28 billion, a PE ratio of -29.84 and a beta of 1.13. The firm has a 50 day simple moving average of $27.82 and a two-hundred day simple moving average of $19.38.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same period in the previous year, the company posted ($1.38) earnings per share. On average, analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total value of $700,000.00. Following the completion of the sale, the insider directly owned 212,122 shares in the company, valued at approximately $7,424,270. The trade was a 8.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 60,000 shares of company stock valued at $1,725,000. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. CWM LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 6.7% in the 3rd quarter. CWM LLC now owns 12,179 shares of the biotechnology company’s stock worth $420,000 after acquiring an additional 764 shares during the last quarter. Oak Ridge Investments LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 2.5% in the 1st quarter. Oak Ridge Investments LLC now owns 33,734 shares of the biotechnology company’s stock worth $430,000 after acquiring an additional 823 shares during the last quarter. Resona Asset Management Co. Ltd. lifted its holdings in shares of Arrowhead Pharmaceuticals by 8.7% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company’s stock worth $180,000 after acquiring an additional 900 shares during the last quarter. Empowered Funds LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 979 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 64.4% in the 3rd quarter. GAMMA Investing LLC now owns 2,626 shares of the biotechnology company’s stock worth $91,000 after acquiring an additional 1,029 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.